teclistamab,talquetamab
genmab,janssen
['talquetamab', 'teclistamab', 'mmsm']
 in conclusion, teclistamab plus talquetamab is the first-ever reported dual-specific bispecific combination in hematologic malignancies, said mar a-victoria mateos, md, phd. #mmsm #eha2023 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.